Summary:
- Transgene and NEC Corporation have reported positive long-term clinical data for TG4050, an individualized neoantigen cancer vaccine, showing 100% disease-free survival in treated patients after three years.
- The peer-reviewed findings, published in *Nature Communications*, validate the efficacy of this personalized immunotherapy approach in treating head and neck squamous cell carcinoma.